Nationwide epidemiological survey of idiopathic sudden sensorineural hearing loss in Japan by Kitoh Ryosuke et al.
Nationwide epidemiological survey of
idiopathic sudden sensorineural hearing loss
in Japan
著者 Kitoh Ryosuke, Nishio Shin-ya, Ogawa Kaoru,
Kanzaki Sho, Hato Naohito, Sone Michihiko,
Fukuda Satoshi, Hara Akira, Ikezono Tetsuo,
Ishikawa Kotaro, Iwasaki Satoshi, Kaga
Kimitaka, Kakehata Seiji, Matsubara Atsushi,
Matsunaga Tatsuo, Murata Takaaki, Naito
Yasushi, Nakagawa Takashi, Nishizaki Kazunori,
Noguchi Yoshihiro, Sano Hajime, Sato Hiroaki,
Suzuki Mikio, Shojaku Hideo, Takahashi Haruo,
Takeda Hidehiko, Tono Testuya, Yamashita
Hiroshi, Yamasoba Tatsuya, Usami Shin-ichi
journal or
publication title
Acta oto-laryngologica
volume 137
number sup565
page range S8-S16
year 2017
権利 (C) 2017 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis Group
This is an Open Access article distributed
under the terms of the Creative Commons
Attribution-NonCommercial-NoDerivatives
License
(http://creativecommons.org/licenses/by-nc-nd/
4.0/), which permits non-commercial re-use,
distribution, and reproduction in any medium,
provided the original work is properly cited,
and is not altered, transformed, or built upon
in any way.
URL http://hdl.handle.net/2241/00146716
doi: 10.1080/00016489.2017.1297537
Creative Commons : 表示 - 非営利 - 改変禁止
http://creativecommons.org/licenses/by-nc-nd/3.0/deed.ja
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=ioto20
Download by: [University of Tsukuba] Date: 04 July 2017, At: 18:39
Acta Oto-Laryngologica
ISSN: 0001-6489 (Print) 1651-2251 (Online) Journal homepage: http://www.tandfonline.com/loi/ioto20
Nationwide epidemiological survey of idiopathic
sudden sensorineural hearing loss in Japan
Ryosuke Kitoh, Shin-ya Nishio, Kaoru Ogawa, Sho Kanzaki, Naohito Hato,
Michihiko Sone, Satoshi Fukuda, Akira Hara, Tetsuo Ikezono, Kotaro
Ishikawa, Satoshi Iwasaki, Kimitaka Kaga, Seiji Kakehata, Atsushi Matsubara,
Tatsuo Matsunaga, Takaaki Murata, Yasushi Naito, Takashi Nakagawa,
Kazunori Nishizaki, Yoshihiro Noguchi, Hajime Sano, Hiroaki Sato, Mikio
Suzuki, Hideo Shojaku, Haruo Takahashi, Hidehiko Takeda, Testuya Tono,
Hiroshi Yamashita, Tatsuya Yamasoba & Shin-ichi Usami
To cite this article: Ryosuke Kitoh, Shin-ya Nishio, Kaoru Ogawa, Sho Kanzaki, Naohito Hato,
Michihiko Sone, Satoshi Fukuda, Akira Hara, Tetsuo Ikezono, Kotaro Ishikawa, Satoshi Iwasaki,
Kimitaka Kaga, Seiji Kakehata, Atsushi Matsubara, Tatsuo Matsunaga, Takaaki Murata, Yasushi
Naito, Takashi Nakagawa, Kazunori Nishizaki, Yoshihiro Noguchi, Hajime Sano, Hiroaki Sato, Mikio
Suzuki, Hideo Shojaku, Haruo Takahashi, Hidehiko Takeda, Testuya Tono, Hiroshi Yamashita,
Tatsuya Yamasoba & Shin-ichi Usami (2017) Nationwide epidemiological survey of idiopathic
sudden sensorineural hearing loss in Japan, Acta Oto-Laryngologica, 137:sup565, S8-S16, DOI:
10.1080/00016489.2017.1297537
To link to this article:  http://dx.doi.org/10.1080/00016489.2017.1297537
© 2017 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group
Published online: 10 Apr 2017.
Submit your article to this journal 
Article views: 245
View related articles 
View Crossmark data
Citing articles: 2 View citing articles 
RESEARCH ARTICLE
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ABSTRACT
Objectives: Using a large-scale nationwide survey database, we investigated the epidemiological char-
acteristics for idiopathic SSNHL in Japan.
Methods: The subjects for this analysis were patients registered in a Japanese multicentre database
between April 2014 and March 2016. A total of 3419 idiopathic SSNHL patients were registered in the
database, and the clinical characteristics of the idiopathic SSNHL patients were obtained. Several fac-
tors associated with the severity of hearing impairment and prognosis were then investigated.
Statistical analysis was performed to clarify the factors associated with the severity of hearing impair-
ment and prognosis.
Results: There were significant correlations between the severity of hearing loss and diabetes mellitus,
kidney disease, past history of brain infarction, heart disease, age (under 16 years/elderly), and symp-
toms of vertigo/dizziness. We also analyzed the prognostic factors for idiopathic SSNHL, and found that
the severity of hearing loss (Grade 3 or 4), heart disease, aged 65 years or over, time from onset to treat-
ment (over 7 days), and symptoms of vertigo/dizziness were all significantly related to poor prognosis.
Conclusion: The present large-scale clinical survey revealed current epidemiological trends for idio-
pathic sudden sensorineural hearing loss (SSNHL) and various factors associated with the severity of
hearing impairment and prognosis.
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Introduction
Idiopathic sudden sensorineural hearing loss (SSNHL) is
among those diseases specified by the Japanese government
as ‘intractable diseases’ resulting from an unidentifiable
cause and without a clearly established treatment, and entail-
ing a considerably high risk of disability.
In Japan, nationwide epidemiological surveys of idio-
pathic SSNHL have traditionally been conducted by the
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Research Committee of the Ministry of Health and
Welfare for Acute Profound Deafness [1–2]. After 2014, the
framework of the Research Committee was changed, and the
epidemiological surveys of hearing disorders, including idio-
pathic SSNHL, have since been conducted as part of the
Research on Measures for Intractable Diseases. In connec-
tion with this epidemiologic survey, a multicentre database
was constructed, with data for 3419 idiopathic SSNHL
patients registered to date.
In this report, we present our findings regarding the clin-
ical features of idiopathic SSNHL based on an analysis of
the epidemiologic survey database.
Material and methods
The subjects (n¼ 3419) for this analysis were patients regis-
tered with the abovementioned multicentre database
between April 2014 and March 2016. Thirty university hos-
pitals and medical centers participated in this epidemiologic
survey. Idiopathic SSNHL was defined according to criteria
established by the Sudden Deafness Research Committee of
the Ministry of Health and Welfare, Japan (2012). Details of
the criteria are shown in Table 1 [3]. We excluded patients
for whom data were incomplete.
Audiometric and recovery assessment
All data, including the hearing thresholds in the audiograms,
symptoms and complications, were entered in this epidemio-
logic database. The initial audiogram grading (Table 2) and
recovery criteria (Table 3), as defined by the Ministry of
Health and Welfare in Japan [2], were obtained from the
audiogram data.
Statistical analysis
The statistical analysis was performed using Pearson’s
chi-squared test for univariate analysis, and a stepwise logisti-
c-regression model (Wald test) for multivariate analysis. A p
value<.05 was considered significant. Odds ratios were calcu-
lated with 95% confidence intervals. The PSAW Statistics ver-
sion 18.0 (SPSS Inc., Chicago, IL) was used for all analysis.
Results
Characteristics of the included patients
The clinical characteristics, complications and symptoms of
the patients included in this study are given in Table 4.
A large number of idiopathic SSNHL patients (3419
patients) were registered in the database. The average patient
age was 54.2 years (SD¼ 17.0), with the highest proportion
of patients in the 60–69 years age group. The distributions
of idiopathic SSNHL patients in this survey for men and
women in each age group are shown in Figure 1. The aver-
age time from onset to the start of treatment was 6.0 days
(SD¼ 23.3), with the majority of patients (94.0%) beginning
treatment within two weeks of onset.
In this study, we screened the patient medical history
database to identify associations between idiopathic SSNHL
and factors including diabetes mellitus, hyperlipidemia, kid-
ney disease, brain infarction, and heart disease. Diabetes
mellitus was reported in 547 (17.1%), hyperlipidemia in 342
(11.2%), kidney disease in 146 (4.8%), brain infarction in 96
(3.2%), and heart disease in 356 (11.7%) patients. Among
the total patients, 1129 (35.3%) reported episodes of vertigo/
dizziness, and 2451 (77.8%) reported episodes of tinnitus.
Analysis of factors associated with the severity
of SSHNL
The initial pure tone average (PTA) of the affected ear was
calculated for all patients, with the average found to be
69.2dB (SD¼26.2). The distribution of hearing grades is
given in Figure 2.
We next divided the patients into the mild hearing loss
group (Grade 1 and 2) and the severe hearing loss group
(Grade 3 and 4) to analyze the factors associated with the
severity of SSHNL. The results of the univariate statistical
analysis showed that there were significant correlations
between the severity of hearing loss and diabetes mellitus,
kidney disease, heart disease, past history of brain infarction
and symptoms of vertigo/dizziness. Being aged under 16
Table 1. Criteria for the diagnosis of idiopathic SSHNL.
Main symptoms
Suddden onset
Sensorineural hearing loss, usually severe
Unknown etiology
For reference
Hearing loss (i.e. hearing loss of 30dB or more over three consecutive
frequencies)
Sudden onset of hearing loss, but may progressively deteriorate over 72h
No history of recurrent episodes
Unilateral hearing loss, but may be bilateral at the onset
May be accompanied by tinnitus
May be accompanied by vertigo, nausea, and/or vomiting, without recurrent
episodes
No cranial nerve symptoms other than from cranial nerve VIII
Definite diagnosis; all of the above main symptoms are present
Table 2. Criteria for the grading of hear-
ing loss in idiopathic SSNHL.
Grade Criteria
1 PTA <40 dB
2 40 dB PTA <60 dB
3 60 dB PTA <90 dB
4 90dB PTA
This grading system was established by
the Research Committee of the Ministry
of Health and Welfare in Japan in 1988.
PTA, arithmetic mean of the five fre-
quencies (250, 500, 1000, 2000, and
4000 hz).
Table 3. Hearing improvement criteria for SSHNL as defined by the Ministry
of Health and Welfare in Japan.
Hearing improvement status Criteria
Complete recovery All five frequencies in the final audiograms are
20 dB or less, or improvement to the same
degree of hearing in the unaffected side
Marked improvement PTA improvement 30 dB
Slight improvement 10 dB PTA improvement <30 dB
No change PTA improvement <10 dB
PTA, arithmetic mean of the five frequencies (250, 500, 1000, 2000, and
4000 hz).
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years or 65 years was also significantly related to severe
hearing loss (Grade 3 or 4). A multivariate logistic-regres-
sion analysis of hearing loss grade, adjusted for gender, age,
symptoms, and the above-mentioned comorbidities, revealed
a significantly higher probability of severe hearing loss in
the patients with vertigo/dizziness, diabetes mellitus, heart
disease, or those aged 65 years or over (Table 5).
Type of treatment
Patient distribution by type of treatment, with a focus on
corticosteroids, is shown in Figure 3(A). The majority of
patients (92%) were administered some type of corticoster-
oid, with systemic corticosteroid therapy being the most
common (83%) and only 9% of patients in this study receiv-
ing intratympanic corticosteroids.
We also examined the use of other drugs concomitantly
with corticosteroids. Specifically, adenosine triphospate
(ATP), vitamin B12 (Vit B12) , and prostaglandin (PG) were
recorded in the database. The pattern of concomitant drug
use is shown in Figure 3(B). Corticosteroids with all drugs
mentioned above (ATP, Vit B12, and PG) (Treatment A)
accounted for 29.9% and corticosteroids with ATP and Vit
B12 (without PG) (Treatment B) accounted for 61.6% of
patients in this study. Only 3.7% of patients received corti-
costeroids alone (without any concomitant drugs)
(Treatment C). Among these three types of concomitant
drug use, patients with severe hearing loss (Grade 3 or 4)
more frequently received Treatment A, accounting for 75.1%
in that treatment group, 56.8% in the Treatment B group
and 50.5% in the Treatment C group. Statistically significant
differences were observed in the severity of hearing loss
between Treatment A and Treatment B or C (Figure 3(C)).
Based on these findings, it appears that PG has commonly
been used for patients with severe hearing impairment.
Analysis of factors associated with the prognosis of
idiopathic SSNHL
In this study, the treatment efficacy for all patients, repre-
sented by the recovery criteria in Table 3, was as follows;
complete recovery was observed in 1317 patients (41.2%),
marked improvement in 521 patients (16.3%), slight
Table 4. Characteristics of the included patients.
Number Percentage (%)
All patients 3419
Sex
Male 1771 51.8
Female 1614 48.2
Affected ear
Right 1549 46.0
Light 1761 53.0
Bilateral 31 1.0
Age
15 84 2.6
16-64 2117 66.0
65 1007 31.4
Onset year
before 2000 96 3.0
2001–2005 271 8.4
2006–2010 824 25.4
2011–2015 2034 62.8
2016– 13 0.4
Time from the onset to the start of treatment
 7 days 2682 81.7
8–14 days 405 12.3
 15 days 196 6.0
Comorbidity
Diabetes mellitus 547 17.1
Hyperlipidemia 342 11.2
Kidney disease 146 4.8
Brain infarction 96 3.2
Heart disease 356 11.7
Symptom
Vertigo/dizziness 1129 35.3
Tinnitus 2451 77.8
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Figure 1. Age distribution of males and females in this study. In each gender group, the number of patients gradually increased from the youngest age group to
the 60–69 years age group. The average patient age was 54.2 years (SD ¼17.0).
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improvement in 549 patients (17.2%), and no change in 807
patients (25.3%) (Figure 4). We next divided the patients
into the good prognosis group (complete recovery or
marked improvement) and the poor prognosis group (slight
improvement or no change) to analyze the factors associated
with prognosis, and found that the severity of hearing loss
(Grade 3 or 4), hyperlipidemia, heart disease, aged 65 years
or over, time from onset to treatment (over 7 days) and
symptoms of vertigo/dizziness were significantly related to
poor prognosis based on univariate analysis. We also per-
formed a multivariate analysis, adjusted for gender, age,
symptoms, above-mentioned comorbidities, time from onset
to the start of treatment, and severity (grade) of initial hear-
ing loss. The multivariate analysis showed that
hyperlipidemia, heart disease, age (65 years or over), time
from onset to treatment (over 7 days), and symptoms of
vertigo/dizziness could be considered as independent prog-
nostic factors in relation to recovery. Diabetes mellitus was
correlated with better prognosis based on the multivariate
analysis (no significant correlation was observed in the uni-
variate analysis). Severity of hearing loss was excluded by
the multivariate model (Table 6).
Discussion
This epidemiologic survey was able to accumulate a large
amount of detailed data from thirty university hospitals and
medical centers, and there have been almost no previous
reports of such large-scale clinical analyses. Furthermore, we
could analyze the route of corticosteroid administration
including intratympanic administration. On the other hand,
we could not clarify the incidence of idiopathic SSNHL as
this study was not designed as a complete survey of all
patients in each hospital.
Characteristics of the included patients
The present study demonstrated that the incidence of idio-
pathic SSNHL was highest in both males and females aged
in their 60s, and the average patient age was 54.2 years
(SD¼ 17.0). There was a tendency for the peak incidence to
shift toward the older generation in comparison with the
results of previous surveys in Japan [1].
Grade 1 (PTA < 40dB)
Grade 2 (40dB PTA <60dB)
Grade 3 (60dB PTA <90dB)
Grade 4 (90dB PTA)
494 
(15.2%)820 
(25.1%)
1219 
(37.4%)
728 
(22.3%)
Figure 2. Grade of hearing loss in this study. The grade of hearing loss was
obtained from the initial audiogram, as defined by the Ministry of Health and
Welfare in Japan (Table 2).
Table 5. Analysis of risk factors and odds ratio related to Grade 3/4 hearing loss.
Univariate analysis Multivariate (n¼ 2538)
Factor Number of Grade 3/4 (%) Odds ratio (95%CI) pa Exp(B) (95%CI) pb
Sex
Male 1097/1706 (64.3) Reference Reference
Female 9351543 (60.6) 0.854 (0.741–0.984) .03 .06
Vertigo/dizziness
Negative 1138/2000 (56.9) Reference Reference
Positive 803/1083 (74.1) 2.17 (1.85–2.56) <.01 2.39 (1.99–2.88) <.01
Tinittus
Negative 427/674 (62.5) Reference Reference
Positive 1471/2355 (63.4) 0.96 (0.81–1.15) .68 .98
Diabetes mellitus
Negative 1537/2547 (60.3) Reference Reference
Positive 395/537 (73.6) 1.83 (1.47–2.25) <.01 1.95 (1.52–2.50) <.01
Hyperlipidemia
Negative 1626/2616 (62.2) Reference Reference
Positive 217/328 (66.2) 1.19 (0.94–1.52) .26 .94
Kidney disease
Negative 1747/2807 (62.2) Reference Reference
Positive 104/144 (72.2) 1.16 (1.09–2.29) .02 .49
Brain infarction
Negative 1781/2861 (62.3) Reference Reference
Positive 72/94 (76.6) 1.99 (1.23–3.20) <.01 .2
Heart disease
Negative 1604/2616 (61.3) Reference Reference
Positive 255/345 (73.9) 1.79 (1.39–2.30) <.01 1.39 (1.03–1.88) .03
Age of onset
15 58/81 (71.6) 1.84 (1.13–2.99) .01 Reference
16-64 1197/2071 (56.3) Reference
65 698/984 (70.2) 1.78 (1.54–2.10) <.01 1.70 (1.41–2.05) <.01
aChi-squared test was used for univariate analysis.
bStepwise logistic-regression model (Wald test) was used for multivariate analysis.
In the multivariate analysis, sex, symptoms of tinnitus, comorbidity of hyperlipidemia, kidney disease, and past history of brain infarction
were excluded during statistical processing.
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69% 
1% 
13% 
9% 
8% 
(A) 
(B) 
(C) 
Systemic without intratympanic
Systemic with intratympanic
(initial treatment)
Systemic with intratympanic
(salvage)
Intratympanic
No corticosteroids
29.9% 
61.6% 
3.7% 
2.1% 1.6% 1.1% 
Corticosteroid with ATP, Vit B12
and PG
Corticosteroid with ATP, Vit B12
Corticosteroid without any
concomitant drugs
Corticosteroid with ATP
Corticosteroid with Vit B12
Other combination of drugs
45 
660 
187 
46 
867 
565 
0% 20% 40% 60% 80% 100%
Treatment C
Treatment B
Treatment A
Grade 1/2
Grade 3/4
Figure 3. (A) The types of treatment, with a focus on corticosteroids, are summarized. The majority of patients (92%) were administered some type of corticoster-
oid, with systemic corticosteroid therapy being the most common (83%) and only 9% of patients in this study receiving intratympanic corticosteroids. (B) The pat-
tern of concomitant drugs use is shown. Most patients (96.3%) in this study were treated with corticosteroids together with other concomitant drugs.
Corticosteroids with ATP and Vit B12 (without PG) was the most commonly used combination (accounting for 61.6% of patients). (C) The distribution of the severity
of hearing loss in each treatment group. Treatment A is corticosteroids with ATP and Vit B12 with PG, Treatment B is corticosteroids with ATP and Vit B12 without
PG, and Treatment C is corticosteroids without any concomitant drugs. Treatment A tended to be selected for the patients with severe hearing loss.
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In this study, the patient medical history was included as
part of the clinical data, and diabetes mellitus was reported
in 17.1%, hyperlipidemia in 11.2%, kidney disease in 4.8%,
brain infarction in 3.2%, and heart disease in 11.7% of
patients included in this study. In the Japanese survey
undertaken in 2001, 13.5% of patients had diabetes mellitus,
7.9% had hyperlipidemia, 2.0% cerebral infarction, and 8.0%
had heart disease. Kidney disease was not reported in the
2001 survey [1]. Higher incidences of all comorbidities
reported in the patient medical history were noted in this
study compared to those in the 2001 survey, and this may
reflect an increase in the prevalence of those diseases in the
elderly population itself.
Analysis of factors associated with the severity
of SSHNL
In the present study, the average initial PTA for the affected
ear was 69.2dB (SD¼26.2), and the distribution of hearing
grades was 15.2%, 22.3%, 37.4%, and 25.1%, for Grade 1, 2,
3, and 4, respectively.
Hearing grade distributions in the 2001 survey were
29.7%, 25.3%, 32%, and 13%, and those in the 2012 survey
were 40.6%, 26.1%, 25.5%, and 7.7%, respectively. Based on
these figures, we can see that the proportion of Grade 4
patients was higher in this study than in the past epidemio-
logic surveys in Japan. We speculate that this difference
reflects the higher percentage (100%) of patients treated in
tertiary care centers in this survey compared to the past sur-
veys. In the 2001 survey, the total number of reported
patients was 12,468, and the percentage of patients reported
from university hospitals was 30.7% (3827 patients) [1],
while in the 2012 survey, the actual total number of reported
Complete recovery 
Marked improvement 
Slight improvement 
No change 
1317 
(41.2%)
521 
(16.3%)
549 
(17.2%)
807 
(25.3%)
Figure 4. Treatment outcome, classified according to the recovery criteria
defined by the Ministry of Health and Welfare in Japan (Table 3), for all patients
in this study is shown.
Table 6. Analysis of risk factors and odds ratio related to a poor outcome.
Univariate analysis Multivariate (n¼ 2462)
Factor Number of poor outcomes (%) Odds ratio (95%CI) pa Exp(B) (95%CI) pb
Sex
Male 709/1672 (42.4) Reference Reference
Female 641/1510 (42.5) 1.00 (0.87–1.15) .979 .21
Vertigo/dizziness
Negative 699/1964 (35.6) Reference Reference
Positive 578/1061 (54.5) 2.17 (1.86–2.52) <.01 2.30 (1.93–2.74) <.01
Tinittus
Negative 281/658 (42.7) Reference Reference
Positive 961/2316 (41.5) 0.95 (0.80–1.13) .58 .68
Diabetes mellitus
Negative 1064/2501 (42.5) Reference Reference
Positive 202/523 (38.6) 0.85 (0.70–1.03) .1 0.75 (0.59–0.96) .02
Hyperlipidemia
Negative 1045/2563 (40.8) Reference Reference
Positive 154/324 (47.5) 1.32 (1.04–1.66) .02 1.35 (1.02–1.77) .03
Kidney disease
Negative 1136/2755 (41.2) Reference Reference
Positive 55/141 (39.0) 0.91 (0.65–1.29) .6 .36
Brain infarction
Negative 1154/2807 (41.1) Reference Reference
Positive 43/93 (46.2) 1.23 (0.82–1.86) .32 .61
Heart disease
Negative 1021/2568 (39.8) Reference Reference
Positive 179/338 (53.0) 1.71 (1.36–2.14) <.01 1.61 (1.34–2.15) <.01
Age of onset
15 37/81 (45.7) 1.37 (0.88–2.13) .17 Reference
16-64 779/2045 (38.1) Reference
65 486/959 (50.7) 1.67 (1.43–1.95) <.01 1.61 (1.34–1.94) <.01
Time from the onset to the start of treatment
within 7 days 997/2569 (38.8) Reference Reference
on or after 8 days 317/548 (57.9) 2.16 (1.79–2.61) <.01 2.31 (1.85–2.87) <.01
Initial grade of hearing loss
Grade 1/2 456/1192 (38.3) Reference Reference
Grade 3/4 641/1510 (45.0) 1.32 (1.14–1.53) <.01 .19
aChi-squared test was used for univariate analysis.
bStepwise logistic-regression model (Wald test) was used for multivariate analysis.
In the multivariate analysis, sex, symptoms of tinnitus, comorbidity of kidney disease, past history of brain infarction, and initial grade of hearing
loss were excluded during statistical processing.
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patients was 4753, with the percentage of patients from uni-
versity hospitals only 7.7% (365 patients) [2].
We next examined the factors associated with the severity
of SSHNL. The results of the statistical analysis showed that
there were significant correlations between the severity of
the hearing loss and diabetes mellitus, heart disease, age
(under 16 years or elderly), and symptoms of vertigo/dizzi-
ness. Although kidney disease, past history of brain infarc-
tion, and gender were shown as significant prognostic
factors by univariate analysis, they were excluded by the
multivariate model.
Fukui et al. [4] reported that idiopathic SSNHL patients
with diabetes mellitus had more severe hearing loss than
patients without diabetes mellitus. In that report, patient age
and symptoms of vertigo were also found to be factors
determining the severity of hearing loss, but the effect of
diabetes mellitus on the severity of SSHNL was independent
from those factors. In a temporal bone study of diabetes
mellitus, histological findings revealed thickening of the wall
of the inner ear microvasculature [5], suggesting that dia-
betic patients might be at increased risk of ischemic injury
to the inner ear.
Chronic kidney disease was reported as a risk factor for
the onset of idiopathic SSNHL in a population-based cohort
study from Taiwan (adjusted hazard ratio¼ 1.46) [6], and
several articles showed the presence of cochlear damage in
patients with chronic renal failure on the basis of human
temporal bone studies [7]. In the present study, kidney dis-
ease was shown to be a significant prognostic factor by the
univariate analysis, but was excluded by the multivariate
model. One of the reasons for this discrepancy was that
about half of the patients with kidney disease in this study
had diabetes mellitus, which was more significantly related
to the severity of hearing loss.
Brain infarction (only found to be significant by univari-
ate analysis) and heart disease, which were related to the
severity of idiopathic SSNHL in this study, have also been
thought to be related to micro- or macrovascular insuffi-
ciency. The findings in this study supported the hypothesis
that the disturbance of blood circulation in the inner ear is
one of the possible causes of idiopathic SSNHL.
Type of treatment
Various treatments have been considered for idiopathic
SSNHL. We examined the type of treatment recorded in this
survey, and found that the majority of patients (92%) were
administered some type of corticosteroid.
Amarillo et al. [8] reported on a national survey in Spain,
and found that corticosteroids were used to treat almost all
of the survey subjects (99.7%). Although corticosteroids
have been the mainstay of idiopathic SSNHL treatment since
the report by Wilson et al. [9], Alexander and Harris [10]
reported that the use of some type of corticosteroid was
under 50% in United States in 2006 and 2007, based on the
data from a medical and pharmaceutical claims database. In
fact, initial corticosteroid treatment is regarded as an option
in the American Clinical Practice Guidelines for SSNHL
[11]. Although certain regional differences therefore exist
with regard to treatment, corticosteroids were regarded as
the primary treatment modality in past surveys in Japan
[1,2], and our findings confirm that the use of corticoste-
roids remains the standard treatment in Japan. In this study,
several types of corticosteroids were used, such as prednisol-
one, hydrocortisone, betamethasone, dexamethasone, and
methylprednisolone. Furthermore, the type of administration
(oral or intravenous) and dosage depended on each institu-
tion. Prednisolone was used most frequently (60%), and
hydrocortisone was used in 23% of cases. Further studies are
needed to investigate the effect of corticosteroid type,
administration route, and dosage on the prognosis of
patients with idiopathic SSNHL.
Intratympanic corticosteroids were used in about 23% of
cases in this study, although intratympanic treatment was
never previously reported in epidemiologic surveys in Japan.
As intratympanic administration was reported in 1.4% and
5.5% of cases, respectively, in Spain and the United States,
this suggests that intratympanic treatment is more actively
used in Japan, at least in university hospitals.
With regard to drugs administered concomitantly with
corticosteroids, ATP, vitamin B12, and prostaglandin (PG)
were recorded in the database. ATP and vitamin B12 were
used in about 90% of cases. On the other hand, only 3.6%
of the patients in this survey were treated by corticosteroids
without any concomitant drugs. We also analyzed the rela-
tionship between the type of concomitant drug and the
severity of hearing loss. The results indicated that PG has
been commonly used for patients with severe hearing
impairment. Ogawa et al. reported that no significant differ-
ences were observed in hearing improvement or subjective
symptoms between the group treated with corticosteroids
plus PGE1 and the group treated with corticosteroids plus
placebo (without PGE1); however, the improvement in hear-
ing in the higher frequencies was significantly greater in the
PGE1 group than in the placebo group [12]. In this survey,
it seemed that there were various biases in terms of patient
selection, so a larger prospective, randomized clinical study
is needed to confirm the actual efficacy of the various
treatments.
Analysis of factors associated with the prognosis of
idiopathic SSNHL
In this study, the treatment efficacy for all patients, based
on recovery criteria, was as follows; complete recovery was
observed in 1317 patients (41.2%), marked improvement in
521 patients (16.3%), slight improvement in 549 patients
(17.2%), and no change in 807 patients (25.3%). The 2012
Japanese epidemiologic survey using the same recovery crite-
ria showed that 45.5% of patients achieved a complete
recovery, 11.9% marked improvement, 15.5% slight
improvement, and 27.4% no change [2]. In addition, in a
review of the Japanese literature regarding the treatment
efficacy of idiopathic SSNHL from 1989 to 1998, Asakuma
and Shida [13] reported that a complete recovery was
observed in 30.8%, marked improvement in 24.7%, slight
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improvement in 23.3%, and no change in 21.8% of patients.
It is difficult to compare our findings with those of the pre-
vious reports simply because of differences in the subjects
and treatments; however, good response rate, including a
complete recovery and marked improvement, was roughly
the same in this study as in the past reports.
We also examined the association between the prognosis of
idiopathic SSNHL and several factors, such as hyperlipidemia,
heart disease, aged 65 years or over, time from onset to treat-
ment (over 7 days), and symptoms of vertigo/dizziness.
Univariate and multivariate analysis were used to elucidate the
existence of any relationships to poor prognosis. There was a
statistically significant correlation between the severity of
hearing loss (Grade 3 or 4) alone and poor prognosis in the
univariate analysis, and diabetes mellitus alone was signifi-
cantly related to prognosis in the multivariate analysis.
The presence of vertigo/dizziness was shown to be one of
the negative prognostic factors in this study, and there have
been many reports of the presence of vertigo being related
to poor prognosis in idiopathic SSNHL patients [14,15].
As for comorbidities, our results demonstrated that hyper-
lipidemia and heart disease were related to the prognosis for
idiopathic SSNHL. Although diabetes mellitus was one of the
factors associated with the severity of idiopathic SSNHL, as
described above, it was found that diabetes mellitus tended to
be associated with a better response to the treatment. The
reason for the tendency toward a better recovery in diabetic
patients in our study is speculated to be due to differences in
pathophysiology between diabetic patients and non-diabetic
patients, although the cause remains unclear. For example,
Yandani et al. reported that the genotype of macrophage
migration inhibitory factor (MIF) was associated with the
response to glucocorticoid treatment in patients with idio-
pathic SSNHL [16], and that gene polymorphism of
c.173G>C was also related to the risk of diabetes [17].
Further study is needed to clarify the association between dia-
betes mellitus and sudden hearing loss.
As cardiovascular risk factors are likely to be involved in
the etiopathogenesis of some cases of idiopathic SSNHL, we
recorded heart disease in this survey. In fact, Lin et al. [18]
suggested that idiopathic SSNHL was associated with the
development of myocardial infarction. However, the concept
of heart disease consists of several diseases with different
pathogeneses, such as myocardial infarction, angina pectoris,
and arrhythmia, and we believe that the details of patients
reporting heart disease require further analysis.
Hyperlipidemia was found to be significantly correlated to
poor prognosis in the present study, but the association
between comorbid hypercholesterolemia or hyperlipidemia
and hearing improvement in idiopathic SSNHL has been con-
troversial in previously published articles. Lin et al. reported
that hypercholesterolemia had a significant negative effect on
hearing improvement in a large number of idiopathic SSNHL
patients (781 patients) [19]. The manner in which high choles-
terol interferes with hearing recovery has not yet been investi-
gated; however, high levels of total cholesterol were associated
with an increased pro-thrombotic state.
Many articles in the past have suggested that hearing
recovery is associated with the severity of the initial hearing
impairment [14,15,20]. In the present study, we used the
hearing grade criteria determined by the Research
Committee of the Ministry of Health and Welfare in Japan
(Table 2) for assessing the severity of hearing impairment,
and demonstrated that the Grade 3 or Grade 4 patients
showed worse hearing recovery than Grade 1 or Grade
2 patients. In fact, the rate of patients showing a complete
recovery or marked improvement in each hearing grade was
as follows: Grade 1 was 74.2% (316/442), Grade 2 was
55.4% (340/635), Grade 3 was 59.0% (589/1022), and Grade
4 was 48.0% (314/686). Patients with Grade 4 hearing
impairment had significantly worse hearing outcomes than
the other grades. Furthermore, the number of patients with
Grade 4 hearing impairment showing a complete recovery
was quite small at 10.3%. It appears that a more effective
treatment method should be considered for idiopathic
SSNHL patients with Grade 4 hearing loss.
In this study, the time from the onset of idiopathic
SSNHL to the start of treatment was also identified as a
prognostic factor for hearing recovery, with this result being
consistent with most of the literature [14,15,20]. The length
of time from onset to treatment, however, differed from
those in previous articles. Taken together, our study and
past articles indicate that the initiation of treatment within
at least seven days after onset is recommended for idiopathic
SSNHL patients [20].
Our results also indicated that age was strongly correlated
with hearing recovery, with elderly patients (65 years) car-
rying a significantly higher risk of poor prognosis (OR 1.58).
Although there are some reports that support this relation-
ship between age at onset and hearing recovery in idiopathic
SSNHL patients [14,15], the cutoff for patient age varies. On
the other hand, some reports found no significant correl-
ation between age and hearing recovery [20]. Suzuki et al.
reported on the prediction of hearing outcomes in idiopathic
SSNHL using a multiple regression model, and found that
the regression coefficient for patient age was 0.166dB per
year [15].
Although many articles have reported on the prognostic
factors for idiopathic SSNHL, there is little consensus
regarding the factors predicting hearing recovery in the lit-
erature. In most of the articles, the study population was at
most 300 [14,15,20], whereas in the present study we ana-
lyzed 3419 patients, and such a large-scale clinical survey is
considered to be better suited to the analysis of the various
complicated factors. Development of a more effective treat-
ment for idiopathic SSNHL patients with negative prognos-
tic factors is highly anticipated in the future.
Conclusion
In the present study, we examined the clinical features of
idiopathic SSNHL in a database constructed on the basis of
an epidemiologic survey, and analyzed the factors associated
with the severity of hearing impairment and prognosis.
A large number of idiopathic SSNHL patients (n¼ 3419)
were registered in the database, and the clinical characteris-
tics of the idiopathic SSNHL patients were obtained.
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We examined the factors associated with the severity of
SSHNL, with the results of the statistical analysis showing
significant correlations between the severity of the hearing
loss and diabetes mellitus, past history of brain infarction,
heart disease, age (under 16 years or elderly), and symptoms
of vertigo/dizziness. We also examined the treatment type
recorded in this survey, and found that the majority of
patients (92%) were administered some type of corticoster-
oid. Intratympanic corticosteroids were also used actively in
Japan, at least in university hospitals.
Furthermore, we examined the prognostic factors for
idiopathic SSNHL, and found that the severity of hearing
loss (Grade 3 or 4), heart disease, aged 65 years or over,
time from onset to treatment (over 7 days), and symptoms
of vertigo/dizziness were significantly related to a poor
prognosis.
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